Correlation of Tumor Heterogeneity Assessed in 68Ga-HBED-CC-PET (PSMA-Ligand) with Clinical Response After 223Ra-Dichloride-Therapy in Patients with Bone Metastases of Prostate Carcinoma

摘要: 249 Objectives Prostate carcinomas reveal a high variety of genetic and histological features which account for intratumoural heterogeneity. This could be possible reason varying treatment responses to 223Ra-dichloride-therapy in patients with bone metastases prostate carcinoma. Therefore it is expedient determine pretherapeutic parameters, have predictive value response. 68Ga-HBED-CC-PET shows the PSMA-expression its by increased activity uptake tumour tissue. Using structural analysis images, gain textural parameters assess tumor We investigated number referring heterogeneity analyzed, whether correlates clinical response after thus these has therapy planning outcome. Methods retrospectively analyzed 68Ga-HBED-CC-PET/CT scans 8 cancer before first cycle 223Ra-dichloride (InterviewFusion software, Mediso Medical Imaging, Budapest, Hungary). manually delineated three largest per patient. To investigate within defined Volumes interest (VOIs) we determined - 30 different parameters. All underwent second scan four weeks sixth therapy. The each individual metastasis was this follow-up scan. Furthermore evaluated such as PSA level, alkaline phosphatase (AP), bone-specific (BAP), Eastern Cooperative Oncology Group performance status (ECOG) well For statistical compared above mentioned indicators Results 22 were segmented patients. In 15 found while progress 7 metastases. Student´s t-test (two-sided, unpaired) pretherapy PET/CT significant between post-therapy 68Ga-HBED-CC-PET/CT. addition 11 one routine parameter (maximum lesion diameter) correlate (Spearman´s rank correlation) significantly several correlation coefficients significances are shown table (preAP, preBAP prePSA values begin DeltaAP, DeltaBAP, DeltaECOG indicate change during therapy, empty field indicates no significance). Conclusions These promising results that tumoral using metastasized cancer. future may useful decision making order optimal therapeutic regime terms personalized medicine. However due limited our current evaluation further studies investigating needed.